Phaseline

Targets › ALPL

ALPL (Alkaline phosphatase, tissue-nonspecific isozyme): drug programs, companies and trials

1 program from 1 company in 3 trials: 3 Phase 3; Metabolic and endocrine; next expected readout Feb 2028.

Alkaline phosphatase that metabolizes various phosphate compounds and plays a key role in skeletal mineralization and adaptive thermogenesis. Has broad substrate specificity and can hydrolyze a considerable variety of compounds: however, only a few substrates, such as diphosphate (inorganic pyrophosphate; PPi), phosphocholine, phosphoethanolamine, pyridoxal 5'-phosphate (PLP) and N-phosphocreatine are natural…. (UniProt, P05186)

Open in Phaseline: the race on ALPL, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstraZenecaALXN1850
Alkaline phosphatase enzyme replacement therapy
ALPLPhase 3HypophosphatasiaFeb 2028

Conditions

Hypophosphatasia (3)

Modalities

small molecule (1)

Companies

AstraZeneca (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.